Libida vs Addyi: What Each One Is Approved For, What It Really Costs, and Which One Fits You
Before choosing Libida or Addyi
Under 65 and postmenopausal? Addyi is the better-evidenced default. On-demand, needle-free use may change the answer. Compare the trade-offs before your first consult.
Disclosure, before you read another word: we do not earn a commission from the Libida or Addyi links on this page. We may earn a commission if you book with Midi Health or Sesame, and every one of those links is labeled where it appears. (Full affiliate disclosure)
Libida vs Addyi: If you're postmenopausal and under 65 with acquired, generalized HSDD, Addyi is the better-evidenced default: it is FDA-approved for your age group, taken nightly, and currently costs $149 a month cash or as little as $20 a month for eligible commercially insured patients. Libida wins when on-demand, needle-free dosing matters more than exact-product FDA review.
But that's the headline, not the whole answer. Four things can flip it, and one of them is a contradiction between Inner Balance's own live pages.
Before you scroll: is either one even for you?
| Option | Best for you if… | Not your first move if… |
|---|---|---|
| Addyi (flibanserin) | You're under 65, you want the option with FDA approval and a trial in postmenopausal women, insurance access matters, and you can take one tablet every night for up to eight weeks before judging it. | You have any liver impairment, take a moderate or strong CYP3A4 inhibitor, cannot follow the alcohol-timing rules, or want something for a specific night. |
| Libida (compounded bremelanotide + oxytocin) | On-demand use is the whole point, you do not want an injection or a nightly pill, and you accept a compounded product whose exact formulation has not been reviewed by FDA. | You need exact-product trial evidence, insurance billing, a public compounding-pharmacy identity, consistent dosing instructions, or a money-back guarantee. |
| Neither, yet | — | Sex hurts, your desire dropped after a new medication, the change does not distress you, or another medical, psychiatric, relationship, or medication cause has not been ruled out. Start with the cause. |
The four things that flip the answer:
- Any liver impairment or a moderate-to-strong CYP3A4 inhibitor. Addyi is contraindicated with both. That includes drugs such as fluconazole, ciprofloxacin, diltiazem, erythromycin, clarithromycin, ketoconazole, and itraconazole. Grapefruit juice can also raise flibanserin levels. Not “use caution.” Contraindicated.
- You're 65 or older. Addyi is not indicated at 65 or older. Libida has no FDA-approved indication at any age, and the approved bremelanotide product, Vyleesi, is limited to premenopausal women. Skip to what to do instead.
- You drink in the evening. Addyi's boxed warning creates a real timing rule. Vyleesi's label has no alcohol restriction, but that does not prove a Libida-specific alcohol interaction profile.
- You want something for a specific night. Addyi is not an acute medication. Nothing in its label supports taking it as a one-night event drug. Libida is sold specifically for on-demand use.
Libida vs Addyi: what changes the decision in 60 seconds?
Last verified August 2026. Prices and policies below are tied to the current public pages reviewed on August 11, 2026.
| Decision fact | Addyi | Libida |
|---|---|---|
| What it is | FDA-approved prescription tablet containing flibanserin 100 mg | Compounded sublingual prescription tablet marketed as bremelanotide plus oxytocin |
| FDA-approved? | Yes — NDA 022526 | No. Compounded drugs are not FDA-approved |
| Covers postmenopausal women? | Yes, if younger than 65 and the full HSDD criteria are met | No FDA-approved indication. Vyleesi, the approved bremelanotide injection, is not indicated after menopause |
| How you take it | One tablet every night at bedtime | One tablet under the tongue before anticipated intimacy, according to Inner Balance |
| How fast | Not on demand. Some patients notice change around four weeks; stop after eight weeks if there is no improvement | Company says 30–60 minutes, with effects lasting 24–72 hours; those are provider claims, not findings from an FDA review of Libida |
| Current public price | $149 a month cash through PhilRx; eligible commercial-insurance claims conflict between $20 a month and $40 a year on Addyi's own pages | Product page says “from $99.70/mo”; a separate Inner Balance pricing page lists $199 monthly, $249 every two months, $299 every three months, and a $249 one-time pack |
| Insurance | Coverage is possible; prior authorization may be needed; manufacturer savings have eligibility restrictions | Inner Balance presents Libida as direct cash-pay and does not advertise insurance billing for it |
| Refund protection | Pharmacy and telehealth terms depend on the route used | Libida is excluded from Inner Balance's money-back guarantee |
| The real trade | More exact-product evidence, more daily rules | More convenience, more product-specific unknowns |
The HRT Index is the independent decision resource for online menopause and HRT care — comparing telehealth providers on clinical legitimacy, care quality, medication fit, price transparency, and access, with every claim verified and dated, so women can choose the path that fits their situation before their first consult.
The right online HRT provider isn't the same for every woman — it depends on your symptoms, your age and whether you have a uterus, your medication route preference (patch, pill, gel, or vaginal estrogen), your risk history, your insurance or cash-pay situation, and your state. Some situations belong with an in-person clinician first. Because a general answer can't resolve those for you, use The HRT Index's Find My HRT Path tool to match your situation to the right provider — and to flag when online care isn't the right starting point — before your first consult.
What we actually verified
We think you should know exactly what's behind this page before you trust a word of it.
What we did:
- Read the current Addyi prescribing information, revised December 2025, including the postmenopausal study tables and boxed warning.
- Read the current Vyleesi prescribing information, revised March 2024 and updated on DailyMed in November 2025.
- Pulled Inner Balance's live Libida product page, PT-141 education page, pricing page, HSA/FSA page, and refund policy on August 11, 2026 and logged the places they disagree.
- Recalculated every cost-per-tablet and average monthly outlay from Inner Balance's published charges.
- Checked Addyi's current pricing against the manufacturer access page and FAQ, then kept both conflicting insured-price claims visible instead of choosing the prettier one.
- Checked the current FDA approval databases for an approved generic flibanserin product.
What we did not do:
- Buy or take either product.
- Speak to Inner Balance's clinicians.
- Verify Libida's dispensing pharmacy, certificate of analysis, exact prescription strength, or the protocol behind Inner Balance's internal customer results. Those details were not publicly reproducible on the pages reviewed.
What we earn: nothing from the Libida or Addyi links on this page. A commission if you book with Midi Health or Sesame.
We publish no star rating for either product. We'll explain why near the end, and it's a reason worth reading.
Libida vs Addyi: what's the actual difference?
Answer capsule: Addyi is FDA-approved flibanserin 100 mg, taken every night at bedtime and evaluated as that exact tablet. Libida is a compounded sublingual prescription product marketed as a combination of bremelanotide and oxytocin, taken before sex. One is a daily background medication; the other is an on-demand product. They are not two versions of the same drug.
They do not even work through the same primary receptor system.
Addyi has activity at serotonin receptors — including 5-HT1A agonist and 5-HT2A antagonist activity — and affects dopamine and norepinephrine signaling. The honest part, printed in the label itself: the exact mechanism by which it improves HSDD is not known. Steady state takes about three days. Clinical benefit is judged over weeks, not hours.
Bremelanotide, one of the ingredients Inner Balance says is in Libida, is a melanocortin receptor agonist. Vyleesi's label says the mechanism by which bremelanotide improves HSDD is unknown. Inner Balance adds oxytocin and markets that addition as support for bonding and emotional connection, but we found no published trial of Libida's exact sublingual combination.
Neither one is “female Viagra.” Viagra primarily changes genital blood flow. These products are intended to affect desire through central nervous-system pathways.
What “FDA-approved” actually buys you
Not a guarantee that it works for you. What it buys is narrower and more useful than that:
- Premarket review of a specific dose, ingredient, route, formulation, and manufacturing package
- A public prescribing label with contraindications, warnings, interactions, and trial adverse-event rates
- A defined population in which that exact product was studied
- A standardized product an insurer can evaluate for formulary coverage
What “compounded” actually means here
A compounded drug can meet a real patient need when an FDA-approved product is not medically appropriate for that patient. But the FDA is direct: compounded drugs are not FDA-approved, and FDA does not verify their safety, effectiveness, or quality before they are marketed.
That distinction is the quiet spine of this comparison. It does not prove Libida cannot help someone. It means evidence for Vyleesi, bremelanotide as an ingredient, or intranasal oxytocin cannot be treated as evidence for Libida's exact sublingual combination.
The regulatory line is simple: Addyi is FDA-approved for its labeled population; Libida is a compounded product and is not FDA-approved.
Which one is approved for women after menopause?
Answer capsule: Addyi. On December 13, 2025, FDA expanded Addyi's indication to women younger than 65 with acquired, generalized HSDD, independent of reproductive status. Vyleesi remains approved only for premenopausal women, and its label explicitly says it is not indicated for HSDD after menopause.
This is the fork in the road, and almost nobody publishes it correctly.
Addyi was approved in 2015 for premenopausal women. The December 13, 2025 FDA supplement approval extended the indication to women younger than 65 independent of reproductive status. The current label now covers eligible premenopausal, perimenopausal, and postmenopausal women under 65.
Vyleesi's current label goes the other direction. Its Limitations of Use section says it is not indicated for HSDD in postmenopausal women or in men. That's not an omission. That's a stated boundary.
Inner Balance's product page says Libida works after menopause. That is a provider marketing claim about a compounded product. It is not an FDA-approved indication, and we found no published trial of the exact Libida formulation in postmenopausal women.
Where you stand, exactly
| Where you are | Addyi | Libida | What it means for you |
|---|---|---|---|
| Premenopausal and under 65 | FDA-approved if the full HSDD criteria are met | No FDA-approved indication; the exact compounded product lacks a published trial | Both may come up in a consultation, but only one has exact-product approval |
| Perimenopausal and under 65 | FDA-approved; the current indication is age-based, not menopause-stage-based | No FDA-approved indication | Daily vs on-demand still matters, but regulatory status is not equal |
| Postmenopausal and under 65 | FDA-approved, with a placebo-controlled study in postmenopausal women under 65 | No exact-product approval or published postmenopausal trial located | This is the fork. One has exact-product evidence in your life stage; one has a company claim |
| 65 or older | Not indicated; safety and effectiveness have not been established | No FDA-approved indication, and Vyleesi does not cover postmenopausal women | Neither is an evidence-first online default |
| Any liver impairment | Contraindicated — any degree | Public Libida materials do not establish an equivalent product-specific hepatic-safety profile | Addyi is off the table; Libida still needs a clinician review, not a marketing-page assumption |
| Moderate or strong CYP3A4 inhibitor | Contraindicated | No public exact-product interaction study located | Your full medication list decides this |
| Evening alcohol is common | Possible only if you can follow the boxed-warning timing rules every time | Vyleesi has no alcohol restriction; Libida-specific interaction data were not located | Practical point for an on-demand route, but not proof of equivalence |
Not sure which line you're on?
Menopausal status, your medication list, and your state all change which route is realistic — and sometimes the answer is neither. The HRT Index's Find My HRT Path tool walks through it and flags when online care isn't the right starting point. See which route fits your situation →
What's actually in Libida — and what remains unpublished?
Answer capsule: Inner Balance publicly describes Libida as a compounded sublingual tablet combining bremelanotide and oxytocin. On the public product and education pages we could reproduce on August 11, 2026, the company did not consistently display the exact prescription strengths, inactive ingredients, dispensing pharmacy, or pharmacokinetic data for the combination. Confirm those details from your prescription label before you pay.
This section changed the most during our audit because a dose is not a detail you fill in from memory.
Inner Balance consistently names the two marketed ingredients: bremelanotide and oxytocin. It also consistently describes the route as a sublingual tablet or lozenge. But the live product page we reviewed did not display an exact milligram/IU strength in the checkout-facing copy, and we could not independently reproduce the separate help-center strength disclosure described in the earlier draft.
So we are not publishing an exact strength as a verified fact.
Before the prescription is dispensed, get these five items in writing:
- The exact bremelanotide strength per tablet
- The exact oxytocin strength per tablet
- Every inactive ingredient
- The name and state-license details of the dispensing pharmacy
- The prescribed maximum per 24 hours, per 72 hours, and per month
That is not bureaucracy. It is the minimum information needed to know what you are taking.
The one comparison we will not make
You may see people compare the milligram number on a sublingual Libida prescription with Vyleesi's 1.75 mg injection and draw a conclusion. Don't, and we won't.
A drug absorbed through oral tissue and a drug injected under the skin can have completely different bioavailability and concentration curves. We found no published pharmacokinetic study showing how much bremelanotide from Libida's exact sublingual formulation reaches the bloodstream.
So the number on the label is not the whole question. This is the question, and it's worth writing down:
“Do you have pharmacokinetic data for this specific sublingual formulation — and what evidence supports this prescribed strength?”
Ask it at intake. The answer, or the absence of one, tells you a lot.
Where Inner Balance's dosing rules disagree
We read the current product page and PT-141 education page on the same day.
| Public Inner Balance page | Published maximum | What changes |
|---|---|---|
| Libida product page | One tablet in a 72-hour period | Stricter spacing; no monthly cap shown in the dosing answer we reviewed |
| PT-141 education page | One dose per 24 hours, no more than 8 doses per month | Allows closer repeat dosing but adds a monthly ceiling |
| Vyleesi FDA label | One injection per 24 hours; more than 8 doses per month is not recommended | Applies to the approved 1.75 mg injection, not to Libida |
Those are not interchangeable instructions. The product page's 72-hour rule is more restrictive than the education page's 24-hour rule, while the education page supplies a monthly cap the product page does not put beside its dosing answer.
Do not solve that contradiction yourself. Follow the actual prescription label and ask the prescriber to reconcile it in writing.
Which one has better evidence?
Answer capsule: Addyi has exact-product randomized trial evidence in both premenopausal and postmenopausal women under 65. Vyleesi has exact-product randomized evidence in premenopausal women, but its pivotal trials did not show a statistically significant difference from placebo in satisfying sexual events. Libida's exact sublingual bremelanotide-oxytocin combination has no published randomized trial we could locate.
That last sentence deserves a second read.
A satisfying sexual event is a sexual event the participant recorded as satisfying. It is not a perfect measure of desire, but it is one of the most concrete outcomes in these trials.
Now look at what each approved product's own label showed.
The two-label ledger
Both labels read in full on August 11, 2026: Addyi prescribing information, revised December 2025; Vyleesi prescribing information, revised March 2024.
| Evidence question | Addyi (flibanserin) | Vyleesi (bremelanotide injection) |
|---|---|---|
| Studied after menopause? | Yes. Study 6 randomized 447 women to Addyi and 455 to placebo; the under-65 efficacy population included 430 and 451. Mean age was 55 | No. The pivotal trials enrolled 1,247 premenopausal women, ages 19–56, with a mean age of 39 |
| Satisfying sexual events | Met. Baseline 2.0 per 28 days; mean change +0.9 on Addyi vs +0.6 on placebo; treatment difference 0.4, 95% CI −0.0 to 0.8, p<0.025 | Did not separate from placebo. The label reports p=0.76 and p=0.70 in the two trials |
| Desire score | Met. FSFI-Desire mean change +0.7 vs +0.4; treatment difference 0.3, p<0.0001 | Met. Desire-domain improvements were statistically significant |
| Distress | Met. FSDS-R item 13 change −0.8 vs −0.6; difference −0.2, p<0.01 | Met. Distress-domain improvements were statistically significant |
| How long one dose works | Daily background medication; terminal half-life is about 11 hours | Label says the duration of efficacy after each dose is unknown; terminal half-life is about 2.7 hours |
Now here's the part that made us go back and read the pages twice.
Inner Balance's Libida product page charts “satisfying events per month” and describes internal results from more than 10,000 women. Its PT-141 education page publishes a satisfying-event claim while relying on bremelanotide evidence. But Vyleesi's pivotal trials did not separate from placebo on that endpoint, and Inner Balance does not link a public protocol, comparator analysis, or peer-reviewed paper for the exact Libida product.
On the outcome most women can picture, the approved bremelanotide trial evidence is weaker than the marketing presentation makes it look.
Now the part that's fair to Addyi's critics
We're not going to sell you Addyi by hiding this.
The average advantage was small. In the postmenopausal study, the treatment difference was about 0.4 additional satisfying sexual events per 28 days compared with placebo, and the confidence interval reached the edge of zero. A 2016 systematic review and meta-analysis concluded that the average benefit was marginal relative to adverse effects.
The label's responder analysis is a better way to picture the decision. In the premenopausal trials, the share rating themselves “much improved” or “very much improved” was higher with Addyi than placebo by roughly 8–9 percentage points for satisfying events, 10–13 points for desire, and 7–13 points for distress.
Translate that: roughly one extra woman in ten reported a result she considered meaningfully better than placebo. That's a real effect. It is not a light switch.
One more limitation, and it matters for our readers: the postmenopausal trial excluded women with uncontrolled hypertension, uncontrolled diabetes, cardiovascular disease, uncorrected thyroid disease, and psychiatric conditions. If you're managing several conditions at once, the trial population may not look much like you.
The evidence-distance ladder
Not all evidence points equally close to the thing you're actually swallowing.
- Addyi, the exact product — approved strength, approved route, randomized trials in premenopausal and postmenopausal women, and a public label. Closest possible match to the bottle.
- Vyleesi, the exact product — approved 1.75 mg injection, randomized trials, and a public label. But a different route and a different population from many Libida buyers.
- Bremelanotide as an ingredient — real research, but route and formulation matter.
- Oxytocin as an ingredient — mixed evidence. A randomized trial of long-term intranasal oxytocin found that oxytocin and placebo both improved sexual function, with no treatment effect between them. That was nasal oxytocin, not Libida's sublingual combination.
- Libida, the exact combination — no published randomized trial of the specific sublingual formulation located; company-reported customer outcomes without a public study protocol.
Every rung down is a step farther from the product you're paying for. That's not an accusation. It's the map.
What's the honest catch about Addyi?
Answer capsule: Addyi is not designed or studied to improve desire that night. It is taken every night, some patients begin noticing changes around four weeks, and the label says to discontinue after eight weeks if there is no improvement. You are committing to a nightly prescription with alcohol, interaction, and alertness rules before you know whether you are one of the women it helps.
Let's not dance around this, because it's the reason a lot of women pick the other route.
Addyi is not an event drug. There is no “take it before date night.” If what you want is something you can use for a specific evening, Addyi is the wrong tool and Libida is genuinely built around that preference. That's a real advantage, and we're not going to argue you out of it.
It's also a nightly commitment with rules attached — alcohol cannot be close to the dose, you should not drive or operate machinery for at least six hours after taking it, and several common drugs are incompatible.
But here's the trade, and it's worth understanding before you dismiss it.
Because Addyi is not tied to a specific evening, it is aimed at the background problem women often describe: I love my partner and I never think about sex anymore. That's not a Friday-night problem. It's a persistent desire problem, and a daily treatment model makes sense for the right diagnosis.
You are also not scheduling intimacy around a pre-dose window. And Addyi is the only option in this comparison with a placebo-controlled trial of the exact product in postmenopausal women under 65.
If on-demand use is genuinely the deciding factor, stop reading our recommendation and read the fine print instead. The charge math, refund exclusion, dosing contradiction, and evidence gaps are all laid out below. We'd rather you choose the right route with your eyes open than force the evidence-first winner onto the wrong preference.
If the nightly trade sounds right
Midi Health publicly lists flibanserin (Addyi) and bremelanotide (Vyleesi) among its non-hormonal sexual-wellness prescriptions, alongside vaginal estrogen, systemic estrogen, and testosterone. It is in-network with most PPO plans; self-pay is currently $250 for the first visit and $150 for continued-care visits. Midi cannot treat Medicaid or Medi-Cal patients, even as self-pay; Medicare beneficiaries may self-pay but cannot submit Midi claims. Check Midi coverage and availability → (sponsored link — we may earn a commission)
Can you drink alcohol on Addyi?
Answer capsule: Yes, but not close to the dose. Addyi's boxed warning says to wait at least two hours after one or two standard drinks before taking it at bedtime, skip that night's dose after three or more drinks, and avoid alcohol after the dose until the next day. It is a timing rule, not a lifetime ban.
This is the objection we see most, and most of what's written about it is wrong in one direction or the other.
| Your evening | What the Addyi label says to do |
|---|---|
| 1–2 standard drinks | Wait at least two hours before taking Addyi at bedtime |
| 3 or more standard drinks | Skip that night's dose |
| After taking Addyi | No alcohol until the next day |
A standard drink in the label is one 12-ounce regular beer, 5 ounces of wine, or 1.5 ounces of distilled spirits.
Inner Balance's pages characterize Addyi as a medication you cannot drink on. That is too broad. Alcohol was removed from Addyi's contraindications section in 2019, but it remains in the boxed warning with the timing rules above.
And we are not going to soften why those rules exist. The label reports the death of a 54-year-old postmenopausal woman with hypertension and high cholesterol who reported one to three drinks daily at baseline and died of acute alcohol intoxication 14 days after starting Addyi. Her blood alcohol level at autopsy was 0.289; coronary artery disease was also noted. The label says the relationship to Addyi is unknown.
The current label also says dedicated alcohol-interaction studies were not conducted in postmenopausal women. That's a gap, and you deserve to know it is there.
Libida's side is not as simple as “no restriction.” Vyleesi's approved label does not contain an alcohol restriction, and Inner Balance markets Libida without Addyi's timing rules. But we found no published alcohol-interaction study of Libida's exact bremelanotide-oxytocin sublingual formulation. The practical burden may be lower; the product-specific evidence is also thinner.
Who can't take Addyi at all?
Answer capsule: Addyi is contraindicated in anyone with any degree of liver impairment and anyone taking a moderate or strong CYP3A4 inhibitor. It is also not indicated at 65 or older. If any of those apply, the Addyi side of this comparison ends here.
These are not exotic. That's the problem.
Hard stops — Addyi is contraindicated:
- Any hepatic impairment, any degree. In a study of mild impairment, flibanserin exposure increased about 4.5-fold.
- Moderate or strong CYP3A4 inhibitors, including fluconazole, ciprofloxacin, diltiazem, erythromycin, clarithromycin, ketoconazole, and itraconazole. In one interaction study, fluconazole increased flibanserin exposure about sevenfold; the study stopped early after three of 15 participants developed hypotension or syncope.
- Known hypersensitivity to flibanserin or a component of the tablet.
Grapefruit juice can raise flibanserin exposure and should be avoided.
Timing matters if a contraindicated inhibitor becomes necessary: the label says to start Addyi two weeks after the last dose of the inhibitor, or start the inhibitor two days after the last Addyi dose.
Worth raising with your prescriber, not automatic stops:
- Strong CYP2C19 inhibitors, including some proton-pump inhibitors, SSRIs, benzodiazepines, and antifungals listed by the label, can increase flibanserin exposure.
- Oral contraceptives and other weak CYP3A4 inhibitors can raise exposure; stacking several inhibitors can matter.
- Addyi increased digoxin total exposure about twofold and peak concentration about 1.5-fold, so monitoring may be needed.
- Other sedating drugs can add to central-nervous-system depression.
- CYP2C19 poor metabolizers clear flibanserin more slowly; the label estimates prevalence at roughly 2–5% in White and Black populations and 2–15% in Asian populations.
The label also reports an increase in malignant mammary tumors in a two-year mouse study at exposures above the human exposure. The clinical significance is unknown. We're telling you because it is in the label.
The question underneath all of this
The Addyi and Vyleesi labels define the target diagnosis around the same core exclusion: the low desire is not caused by another medical or psychiatric condition, relationship problem, or medication or drug effect.
Read that again, because it does a lot of work.
If you started an SSRI and your desire fell off a cliff afterward, that medication needs review before you stack a desire drug on top. Do not stop an antidepressant on your own. If sex hurts, desire often follows pain — treat the pain. Thyroid disease, depression, sleep loss, relationship distress, and genitourinary syndrome of menopause can all matter.
That's honest medicine. It's also the reason a $249 purchase might be the wrong first move.
Who shouldn't take Libida?
Answer capsule: Inner Balance publishes different safety and dosing gates on different live pages. The product page says not to use Libida with uncontrolled blood pressure, untreated heart disease, or pregnancy. Its PT-141 education page adds known cardiovascular disease or heart-attack history, stroke history, and breastfeeding. The checkout-facing page carries the shorter list.
We pulled both on the same day. Here's what we found.
| Topic | Libida product page | Inner Balance PT-141 education page | Vyleesi FDA label |
|---|---|---|---|
| Do not use if | Uncontrolled blood pressure, untreated heart disease, pregnancy | Uncontrolled hypertension, known cardiovascular disease or heart-attack history, stroke history, pregnancy or breastfeeding | Uncontrolled hypertension or known cardiovascular disease |
| Maximum frequency | One tablet per 72 hours | One dose per 24 hours, no more than 8 per month | One dose per 24 hours; more than 8 per month not recommended |
| Nausea framing | Described as mild and often limited to the first dose | Uses the approximately 40% figure drawn from bremelanotide injection trials | 40% with Vyleesi; 13% required anti-nausea medication and 8% discontinued |
| Duration | “Up to 72 hours” or “24–72 hours” | “May last 24–72 hours” | Duration of efficacy after each dose is unknown |
| Onset | 30–60 minutes | 45–60 minutes | Administer at least 45 minutes before anticipated activity; exact onset is not established in the label |
“Untreated heart disease” and “known cardiovascular disease” are not the same gate. A person whose heart disease is being treated still has known cardiovascular disease. Vyleesi's contraindication does not disappear because treatment is working.
That's a materially different screen, and the narrower wording is on the page with the buy button.
The pigmentation language also matters. Inner Balance says the roughly 1% rate occurred when women exceeded the recommended dose. Vyleesi's label says focal hyperpigmentation was reported in 1% of patients who received up to eight doses a month, and resolution was not confirmed in some patients.
What we'll credit Inner Balance for
We're not here to run a hit piece, and several disclosures are better than the industry average:
- The product page says Libida is compounded individually and that its statements have not been evaluated by FDA.
- The PT-141 education page plainly identifies the product as compounded and clinician-guided.
- The product page's one-tablet-per-72-hours ceiling is stricter than Vyleesi's one-per-24-hours rule.
- The company publishes a dedicated refund policy instead of hiding the absence of a guarantee entirely.
The problem is not one dramatic lie. It is that a woman reading the checkout page can receive a different safety picture from a woman reading the education page.
Libida vs Addyi cost: which one is actually cheaper?
Answer capsule: At the current cash prices, Addyi is $149 every month. Libida's recurring plans average about $99.67, $124.50, or $199 a month — but the lower averages require $299 every three months or $249 every two months up front, and Libida is excluded from Inner Balance's money-back guarantee. Eligible commercial Addyi coverage can beat every Libida plan.
The comparison everyone gets wrong is that these products are not sold in the same unit.
What Addyi costs
| Route | Current public claim | What to verify |
|---|---|---|
| PhilRx cash | $149 per month, including home delivery | Confirm at enrollment; PhilRx is the fulfillment pharmacy |
| PhilRx with eligible commercial insurance | Addyi's access page says as little as $20 per month | Eligibility restrictions apply; coverage and prior authorization vary |
| PhilRx with eligible commercial insurance | Addyi's FAQ also says as little as $40 per year | This conflicts with the $20/month claim on the same FAQ and other official pages |
| Local pharmacy coupon | Official FAQ says as low as $20 per month for eligible patients | Local stock and coupon eligibility vary |
Notice rows two and three. Addyi's own official FAQ currently publishes both “$20 per month” and “$40 per year” for commercially insured patients. That's not our estimate. It is a live manufacturer inconsistency.
We're not averaging them and we're not picking the prettier one. Get your exact monthly and annual amount during enrollment.
Addyi is supplied in bottles of 30 tablets. At the $149 cash price, that's about $4.97 per nightly tablet.
What Libida costs
Inner Balance's product page says “From $99.70/mo.” Its separate pricing article supplies the package details. We recalculated the rest:
| Published option | Charge cadence | Tablets | Cost per tablet | Average monthly outlay |
|---|---|---|---|---|
| One-time purchase | $249 once | 10 | $24.90 | Not a recurring monthly plan |
| Monthly subscription | $199 every month | 10 | $19.90 | $199.00 |
| Two-month subscription | $249 every two months | 20 | $12.45 | $124.50 |
| Three-month subscription | $299 every three months | 30 | $9.97 | $99.67 |
Three things fall out of that table.
One: the “from $99.70/mo” teaser matches the three-month plan's arithmetic. $299 divided by three is $99.67. The product page does not put the $299 upfront charge beside the teaser.
Two: Inner Balance labels the $249-for-20 plan “best value,” but the $299-for-30 plan has the lower cost per tablet. $12.45 versus $9.97. Their own label and their own math point in different directions.
Three: the annual difference is enormous. The $199 monthly plan costs $2,388 a year for 120 tablets. Four $299 three-month charges cost $1,196 for the same 120 tablets. Same quantity. A $1,192 difference.
The real cash-outlay comparison
| Plan | Amount charged when billed | Average monthly cost | Compared with Addyi cash |
|---|---|---|---|
| Libida — 30 tablets every 3 months | $299 | ~$99.67 | About $49 less per month on average, but $299 leaves your account at once |
| Libida — 20 tablets every 2 months | $249 | $124.50 | About $24.50 less per month on average, but $249 upfront |
| Addyi cash through PhilRx | $149 monthly | $149 | Predictable monthly charge; 30 nightly doses |
| Libida — 10 tablets monthly | $199 | $199 | $50 more per month than Addyi cash |
| Addyi with eligible commercial coverage | Confirm during enrollment | Official pages claim $20/month or $40/year | Potentially far cheaper than every Libida plan |
Usage frequency changes how long your tablets last, not what an auto-renewing subscription charges. If you use two tablets a month but stay on a 30-tablet-every-three-month subscription, another shipment can arrive long before the first box is gone.
That is why the right question is not “What does one experience cost?” It is:
“What amount will be charged, on what date, how many tablets will ship, and what happens if I still have most of the previous supply?”
The thing nobody tells you before you pay
Libida is excluded from Inner Balance's money-back guarantee. The current refund policy says its refund program applies to Oestra and BodyMatched, not Libida.
The product page says “Cancel anytime.” Cancellation can stop a future renewal. It does not turn already-dispensed prescription medication into a refundable purchase.
So do this before taking the biggest discount: start with the smallest quantity that lets you evaluate the prescription without creating a large non-refundable stockpile. Prove it fits. Then decide whether the lower per-tablet rate is worth the upfront charge and renewal cadence.
One more unresolved item: the Libida product page displays “HSA/FSA eligible,” while Inner Balance's dedicated HSA/FSA page says only Oestra is currently eligible. We are quoting both and picking neither. If pre-tax dollars are the reason this feels affordable, get written confirmation before paying.
The table above is the checkout and renewal breakdown: billed amount, cadence, tablet count, cost per tablet, and average monthly outlay.
If you already know what you want to ask a prescriber about
Sesame is a self-pay marketplace: you choose a clinician, see the live visit price before booking, and a prescription can be sent to your pharmacy if clinically appropriate. Sesame does not bill health insurance for the visit; medication and lab costs are separate and may be covered by your plan depending on the prescription, lab, and policy. See current menopause-visit options and live prices → (sponsored link — we may earn a commission)
Will insurance cover either one?
Answer capsule: Addyi may be covered by commercial prescription insurance, and the manufacturer offers savings for eligible commercially insured patients. Inner Balance presents Libida as a direct cash-pay product and does not advertise insurance billing for it. Do not assume “HSA/FSA eligible” means insurance-covered — those are different questions.
This is the single biggest financial difference between the two.
Libida: plan on cash pay unless your insurer confirms otherwise in writing. Inner Balance says no insurance is needed and publishes direct subscription and one-time prices. We found no public Libida formulary or insurance-billing process.
Addyi: coverage is possible, and it is worth checking. PhilRx advertises prior-authorization support and automatically applies the manufacturer coupon when eligible. Your plan can still deny coverage, impose prior authorization, or set a different copay.
Two limits to know:
- The current coupon terms cover eligible commercially insured or eligible uninsured patients and exclude prescriptions reimbursed in whole or in part by Medicare, including Medicare Advantage and Medicare Parts A, B, and D; Medicaid; TRICARE; VA or Department of Defense programs; CHAMPUS; Puerto Rico government plans; or another federal or state health program.
- Medicare Part D and commercial formularies vary. Do not budget around a blanket “covered” or “not covered” answer without checking the actual plan.
If you have commercial insurance, this is the whole ballgame. The evidence question and the price question can point in the same direction — but only after the insurer approves it.
More on coverage across menopause care: HRT costs in 2026.
Is there a generic Addyi, and why might a pharmacy not stock it?
Answer capsule: As of August 11, 2026, we found no FDA-approved generic flibanserin product in FDA's approval databases. Addyi is still the approved brand product. PhilRx is the manufacturer's fulfillment pharmacy, but local pharmacy pickup is also possible with the current coupon route; availability and price should be confirmed before the prescription is sent.
We chased this one down because “flibanserin” is the generic name of the drug, which is not the same thing as an approved generic product.
Flibanserin is the nonproprietary ingredient name. Addyi is the brand name. An FDA-approved generic would require its own approved application and therapeutic-equivalence listing. We did not find one in Drugs@FDA or the Orange Book.
That means a website selling a cheap “generic Addyi” without a legitimate US prescription and pharmacy chain deserves scrutiny. A lower price does not create an FDA-approved generic.
Three stale claims worth correcting
| What you'll still read | What's current |
|---|---|
| “Addyi is only for premenopausal women” | Out of date since December 13, 2025. The indication now covers eligible women younger than 65 independent of reproductive status |
| “Only specially certified prescribers and pharmacies can handle Addyi” | The current prescribing and access pages do not impose the old certified-prescriber/certified-pharmacy distribution gate; a licensed clinician can evaluate and prescribe within scope |
| “PhilRx is the telehealth prescriber” | PhilRx is the fulfillment pharmacy. Addyi's online visit is handled by a separate third-party telemedicine provider, then the prescription can be filled through PhilRx |
The practical route: your clinician can send the prescription to PhilRx for the advertised cash or eligible-insurance program, or you can use the official local-pharmacy coupon and confirm stock first. Do not assume every retail pharmacy keeps it on the shelf.
Can you take either one with HRT?
Answer capsule: Menopause hormone therapy and a low-desire medication solve different problems, and one does not automatically replace the other. Addyi's label does not list standard estrogen or progesterone therapy as a blanket contraindication, but the full medication list still matters. Inner Balance markets Libida as compatible with hormone therapy, but we found no public interaction study of its exact compounded combination.
This is probably why you're here, so let's take it seriously.
A lot of women land on this page because HRT fixed everything except this. The hot flashes stopped. Sleep came back. Brain fog lifted. And desire just… didn't return. That does not automatically mean your HRT is failing.
Desire is biopsychosocial. Hormones, pain, sleep, mood, medications, relationship context, stress, and central nervous-system signaling can all be part of it.
Before you add a second medication, rule out two higher-yield fixes:
- If sex hurts or you're dry, treat that first. Systemic hormone therapy does not fully relieve genitourinary symptoms for every woman. Low-dose local vaginal estrogen is one common evidence-based option when appropriate, and other non-estrogen options exist. No desire drug makes painful sex inviting. More on vaginal estrogen.
- If the change followed an antidepressant or another medication, review that first. Both approved HSDD labels exclude desire loss caused by medication. Do not stop or change an antidepressant yourself; take the timeline to the prescriber who manages it.
On combining with HRT specifically:
- Addyi: estrogen and progesterone are not listed as blanket contraindications. The practical review is your liver function, alcohol pattern, sedating drugs, and interaction list. Oral contraceptives increased flibanserin exposure in the label's analysis, so mention them.
- Libida: Inner Balance markets Libida as usable with Oestra and other hormone therapy. That is a provider statement, not a published interaction study of every HRT regimen. Bring the exact names, doses, and routes of everything you take.
And the option neither product replaces: for postmenopausal women with diagnosed HSDD, testosterone has the strongest guideline-level evidence after a formal biopsychosocial assessment. The Global Consensus Position Statement says the only evidence-based indication for testosterone therapy in women is HSDD, and The Menopause Society describes it as an evidence-based option after menopause.
Three caveats belong every time:
- There is no FDA-approved testosterone product specifically indicated for women in the United States, so treatment is prescribed off-label.
- Testosterone is a Schedule III controlled substance in the US. A prescription is legally required, and state and telehealth rules can affect access.
- The consensus evidence does not apply to pellets, injectables, compounded products, or regimens that produce supraphysiologic levels. The goal is female physiologic-range dosing with monitoring.
If you're on HRT and desire is the last symptom standing, testosterone is a conversation many women have not been offered yet. It is not a shortcut, and it is not an over-the-counter add-on.
If HRT fixed everything except this
That conversation needs a clinician who can weigh flibanserin, Vyleesi, testosterone, local vaginal treatment, medication effects, and pain in one visit — not route you automatically to whatever the clinic sells. Midi publicly lists all four medication categories in its sexual-wellness care. Check Midi insurance and availability in your state → (sponsored link — we may earn a commission; Midi cannot treat Medicaid or Medi-Cal patients, and Medicare beneficiaries are self-pay only)
Where can you actually get each one?
Answer capsule: Libida is obtained through Inner Balance's online intake and filled by a pharmacy the public pages reviewed do not name. Addyi can be prescribed by a licensed clinician, through Addyi's third-party online-visit route, or through a menopause practice, then filled through PhilRx or a local pharmacy. The simplest route depends on whether you need a product decision or just a prescription evaluation.
| Route | What it can evaluate | Insurance model | Current verified cost | Watch out for |
|---|---|---|---|---|
| Midi Health | Menopause-focused care; publicly lists Addyi, Vyleesi, testosterone, vaginal estrogen, and systemic estrogen | In-network with most PPO plans; self-pay available | $250 initial visit; $150 continued-care visit if self-pay | Cannot treat Medicaid or Medi-Cal patients. Medicare beneficiaries may self-pay but cannot submit claims |
| Sesame | Marketplace of individual clinicians; low-libido medications may be discussed if clinically appropriate | Self-pay; does not accept insurance | Live price varies by clinician and location; confirm at booking | Visit fee does not guarantee a prescription; medication cost is separate unless stated |
| Addyi's online route | Addyi-focused third-party telemedicine evaluation | Cash or eligible commercial-insurance savings | Online visit currently advertised at $19; Addyi $149/month cash through PhilRx | Addyi only; the telemedicine provider is separate from PhilRx |
| Inner Balance | Libida-focused online intake | Direct cash-pay model | From $99.70/month on product page; package charge depends on plan | No Libida money-back guarantee; public pharmacy identity and exact checkout-facing strength not verified |
| Your existing clinician | Can evaluate causes and alternatives in the context of your full chart | Your usual visit and pharmacy benefits | Your normal cost-sharing | Ask them to review the December 2025 Addyi indication update |
Two things we want to flag, because they cut against our own interest.
First: Addyi has its own direct online route. Start at Addyi's official access page, complete the third-party online evaluation, and — if prescribed — use PhilRx or a local pharmacy. We earn nothing if you use it. For a woman who already knows she wants an Addyi evaluation and does not need a broader menopause workup, that may be the simplest route.
Second: your existing clinician is a legitimate option. If you already have a gynecologist or primary-care clinician who knows your history, you may not need a separate telehealth membership. Bring the current indication and the full medication list.
What if neither one fits?
Answer capsule: If you're 65 or older, have liver impairment, take a contraindicated drug, have cardiovascular risk that makes bremelanotide inappropriate, or have not ruled out pain and medication effects, neither product is a clean online default. The next best step is a full cause review — and, after menopause, a monitored testosterone conversation may belong on the list.
We'd rather send you somewhere useful than keep you reading.
If you're 65 or older: Addyi is not indicated, and Vyleesi does not cover postmenopausal women. Libida does not gain an approved indication just because it is compounded. This is a clinician conversation, not a checkout decision.
If sex is painful: treat that first. Every time. Desire follows comfort, not the other way around. Vaginal estrogen is one common local option when appropriate, but the cause of pain still needs evaluation.
If you're on an SSRI or another medication that changed your desire: talk to the prescriber before adding anything. This may be a medication-management problem, not a missing-drug problem.
If your desire is low but it genuinely does not bother you: you do not meet the HSDD definition used in these labels. Both require marked distress or interpersonal difficulty. A partner's disappointment is not automatically the same as your distress. That's not a technicality — it is the difference between a diagnosis and normal human variation.
If you want the FDA-approved on-demand option: Vyleesi is the 1.75 mg bremelanotide injection for eligible premenopausal women. It is not indicated after menopause, it is contraindicated with uncontrolled hypertension or known cardiovascular disease, and nausea affected 40% of patients in its trials.
If you're postmenopausal with diagnosed HSDD: ask about transdermal testosterone at female physiologic doses. There is no FDA-approved female product in the US, it is off-label, it is a Schedule III controlled substance, and monitoring matters — but the evidence base is stronger than many women are told.
More non-hormonal options for menopause →
What couldn't we verify?
We'd rather name the gaps than fill them with estimates. As of August 11, 2026, we could not publicly reproduce or confirm:
- Libida's dispensing pharmacy identity. The product page says it ships from a certified US pharmacy but does not name it in the public copy reviewed.
- The exact Libida prescription strengths and inactive ingredients on the public checkout-facing and education pages we reviewed.
- Pharmacokinetic data for Libida's exact sublingual bremelanotide-oxytocin formulation.
- A certificate of analysis supporting the “third-party tested for purity” statement.
- A public protocol, comparator, or peer-reviewed report for the product-page claim involving more than 10,000 women.
- Whether Libida is HSA/FSA eligible. The product page says yes; Inner Balance's dedicated page says only Oestra is currently eligible.
- Which insured Addyi teaser is the operative one: $20 a month or $40 a year. Both appear on current official pages.
- Product-specific state availability for Libida. Inner Balance markets broad online access, but prescription eligibility is still confirmed during intake.
And this is why we publish no rating
Inner Balance publishes testimonials on its own product page, including a “verified patient” quote from a 48-year-old customer describing a “mood + libido boost in under 20 mins.” We are not reproducing it as evidence of efficacy. It is a provider-published marketing testimonial about one person's reported experience, and we could not independently authenticate it.
The product page also says more than 10,000 women have tried Libida and reports internal outcomes. Without a public methodology, denominator breakdown, control group, adverse-event accounting, and exact-formulation paper, that number cannot support a star rating from us.
So: no rating, no review schema, and no borrowed five-star certainty.
One more thing worth saying out loud: customer reviews cannot answer the question you came here with. FDA status, exact ingredients, studied population, contraindications, and refund rules are document questions. No number of five-star reviews changes a label.
How we checked this
We follow The HRT Index Verification Standard: we read every published price, separate FDA-approved from compounded, verify state availability and insurance where the public evidence allows it, and re-check on a fixed schedule — top providers monthly, the full roster quarterly. We evaluate on five pillars, in this order: clinical legitimacy, care quality, medication fit, price transparency, and access. We do not publish numeric provider scores.
For this page, on August 10–11, 2026, we read the current Addyi and Vyleesi prescribing information, checked the FDA approval action for Addyi's expanded indication, fetched Inner Balance's live product, education, pricing, HSA/FSA, and refund pages, logged same-day disagreements, recalculated every published Libida package, and checked the current Addyi access and FAQ pricing.
We're an independent publisher, not a clinic. This page is editorial research and has not been reviewed by a clinician — we say that at the top rather than implying otherwise. When a public page changes, the visible verification date changes only after we re-check it.
Editorial standards · Corrections
Frequently asked questions
Is Libida the same as Addyi?
No. Addyi is FDA-approved flibanserin 100 mg taken nightly. Libida is a compounded sublingual product marketed as bremelanotide plus oxytocin and taken before anticipated intimacy. They use different ingredients, dosing models, and regulatory pathways.
Is Libida the same as Vyleesi?
No. Vyleesi is an FDA-approved 1.75 mg bremelanotide injection for eligible premenopausal women. Libida is a compounded sublingual combination that also includes oxytocin. Different route, different formulation, different population evidence, and different regulatory status.
Is Libida FDA-approved?
No. Compounded drugs are not FDA-approved, which means FDA has not reviewed Libida's exact formulation for safety, effectiveness, or quality before marketing. That does not automatically make a compounded prescription unlawful; it does make it different from an approved product.
Does Addyi work for postmenopausal women?
Addyi is FDA-approved for eligible women younger than 65 independent of reproductive status. Its postmenopausal study met the label's desire, distress, and satisfying-event endpoints, but the average advantage over placebo was modest — about 0.4 additional satisfying sexual events per 28 days.
Which one works faster?
Libida is marketed as the faster option: Inner Balance says 30–60 minutes. That is a provider claim about the compounded product. Addyi is not on demand; some patients report changes around four weeks, and treatment should be stopped after eight weeks if there is no improvement.
Can I drink alcohol on Addyi?
Yes, with strict timing. Wait at least two hours after one or two standard drinks before taking the bedtime dose, skip the dose after three or more drinks, and do not drink again until the next day.
Can I drink alcohol with Libida?
Vyleesi's approved label has no alcohol restriction, and Inner Balance markets Libida without Addyi's timing rule. We found no published alcohol-interaction study of Libida's exact sublingual combination, so ask the prescriber for product-specific instructions.
Can I take Libida and Addyi together?
We found no published evidence establishing the safety or effectiveness of combining them. Do not stack two prescription desire treatments without the prescriber who knows your full medication list approving the plan.
Which one is cheaper?
Addyi cash is currently $149 a month through PhilRx. Libida recurring plans average about $99.67, $124.50, or $199 a month, but the two lower averages require $299 or $249 upfront and the product is excluded from Inner Balance's money-back guarantee. Eligible commercial insurance can make Addyi much cheaper.
Can I get a refund on Libida if it doesn't work?
Libida is excluded from Inner Balance's money-back guarantee. “Cancel anytime” can stop a future renewal; it does not promise a refund on prescription medication already dispensed. Start with the smallest practical quantity.
Do I need a prescription for both?
Yes. Addyi is prescription-only, and Inner Balance markets Libida as a clinician-approved prescription product. A seller offering either without a legitimate prescription process is not offering the standard US route described here.
Is Addyi covered by Medicare?
Coverage depends on the specific Part D or Medicare Advantage drug plan. The current manufacturer coupon is not valid for prescriptions reimbursed in whole or in part by Medicare, including Medicare Advantage and Medicare Parts A, B, and D. If your plan does not cover Addyi, the current PhilRx cash price is $149 a month.
Is there a generic Addyi?
We found no FDA-approved generic flibanserin product as of August 11, 2026. “Flibanserin” is the drug's generic ingredient name; that does not mean a lower-cost approved generic version is available.
What's the difference between flibanserin and bremelanotide?
Flibanserin is a nightly tablet with serotonin-receptor activity and a gradual treatment model. Bremelanotide is a melanocortin receptor agonist used in Vyleesi as an on-demand injection. Libida uses a compounded sublingual formulation marketed as bremelanotide plus oxytocin, so Vyleesi's label cannot be copied onto it wholesale.
Is low desire in menopause a hormone problem or a brain problem?
It can be hormonal, pain-related, medication-related, medical or psychiatric, relational, contextual, or mixed. HSDD is diagnosed only after other causes are considered. That is why treating painful sex, reviewing medications, and assessing distress come before choosing a desire drug.
The bottom line
If you're under 65 and past menopause, Addyi is the better-evidenced choice — it is the only one of these two with an FDA-approved indication covering you and a placebo-controlled trial of the exact product in postmenopausal women. If commercial insurance approves it, it can also be the cheaper route by a wide margin.
Two things flip that. If you have any liver impairment or take a moderate-to-strong CYP3A4 inhibitor, Addyi is contraindicated and that side of the decision is over. And if on-demand, needle-free use is genuinely the deciding factor, Libida is built around that preference and Addyi is not. Just know what you're accepting: a compounded formulation with no published exact-product trial or pharmacokinetic study we could locate, inconsistent public dosing and safety instructions, and no money-back guarantee.
If sex hurts, if a medication change triggered the drop, if the low desire does not distress you, or if you're 65 or older — neither is your first move. Fix or identify the cause before adding another prescription.
Whatever you choose, do one thing before you pay: get the exact dose, dispensing pharmacy, maximum frequency, renewal charge, refund terms, and total out-of-pocket amount in writing. Every gap on this page is a gap someone else expected you not to notice.
Still not sure which HRT program is right for you? Take our free matching quiz.
It asks about your symptoms, history, insurance, and state — and flags when online care isn't the right starting point. Your answers are handled under our consumer health data privacy policy.
The HRT Index is reader-supported. We may earn a commission from Midi Health and Sesame, labeled where they appear. We do not earn a commission from the Libida or Addyi links on this page. Compensation never determines our verdict — clinical legitimacy, care quality, medication fit, price transparency, and access do. Read our full disclosure.